ID Source | ID |
---|---|
PubMed CID | 135400435 |
CHEMBL ID | 1454079 |
CHEBI ID | 114226 |
MeSH ID | M0472612 |
Synonym |
---|
MLS000530154 |
4-hydroxy-3-[3-(4-hydroxy-3,5-dimethoxyphenyl)acryloyl]-6-methyl-2h-pyran-2-one |
smr000135131 |
PROBES2_000135 |
PROBES1_000206 |
suptopin-2, >=98% (hplc), solid |
PROBES2_000108 |
NCGC00165895-01 |
CHEBI:114226 |
HMS2386G15 |
AKOS005373395 |
331852-66-5 |
suptopin-2 |
CHEMBL1454079 |
4-hydroxy-3-[3-(4-hydroxy-3,5-dimethoxyphenyl)-1-oxo-2-propenyl]-6-methyl-2h-pyran-2-one |
DTXSID00716250 |
(3z)-3-[(2e)-1-hydroxy-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-en-1-ylidene]-6-methyl-2h-pyran-2,4(3h)-dione |
sr-01000196190 |
SR-01000196190-1 |
J-019074 |
(e)-4-hydroxy-3-(3-(4-hydroxy-3,5-dimethoxyphenyl)acryloyl)-6-methyl-2h-pyran-2-one |
4-hydroxy-3-[(e)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]-6-methylpyran-2-one |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.1886 | 0.1409 | 11.1940 | 39.8107 | AID2451; AID2787 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 17.7828 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 39.8107 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 25.1189 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 28.1838 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
ClpP | Bacillus subtilis | Potency | 28.1838 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 4.6109 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 28.1838 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 100.0000 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 50.1187 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
IDH1 | Homo sapiens (human) | Potency | 32.6427 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 44.6684 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 50.1187 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 22.3872 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Potency | 100.0000 | 0.8913 | 16.5762 | 39.8107 | AID2794 |
transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 22.3872 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
glyceraldehyde-3-phosphate dehydrogenase isoform 1 | Homo sapiens (human) | Potency | 100.0000 | 1.1220 | 11.1877 | 39.8107 | AID2795 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 71.9124 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 71.9124 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 22.3872 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 21.3313 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 39.8107 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 50.1187 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 50.1187 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 1.7783 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
nucleus | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
cytosol | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
cytoskeleton | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
plasma membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
adherens junction | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
focal adhesion | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
extracellular exosome | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |